Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care ... (C Filings. There may be additional risk...)

Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference

Date:3/2/2011

C Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

wsargent@auxilium.com
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions ... of proprietary clinical grade hypothermic storage and ... and contract aseptic media manufacturer , today announced ... & Regenerative Medicine Congress 2013 this week in ... http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) Dr. Aby J. Mathew, BioLife,s ...

(Date:5/23/2013)... SAN DIEGO and PARIS ... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today ... V asodilator I ndependent S tenosis ... late breaking clinical trial session at EuroPCR 2013. These ...

(Date:5/23/2013)... LAUSANNE , Switzerland ... 23, 2013 Cenix BioScience, ... developer specialized in RNAi-, miRNA- and high content-driven ... biopharmaceutical group of companies with a focus on ... medical needs, including oncology and companion diagnostics, today ...

Breaking Medicine Technology:BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5 Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2 Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3 Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4

[0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress [0] Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 [0] Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers

... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...

... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...

Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4

Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference

(Date:5/23/2013)... (PRWEB) May 23, 2013 Teen birth rates ... according to new data released today by the ... the teen birth rate dropped at least 15% in 48 ... , There were also dramatic declines among all racial/ethnic groups ... , Birth rates declined 40% or more for Hispanic teens ...

(Date:5/23/2013)... To better serve the architecture and ... to announce the release of its new selections ... division products. Provided by Koroseal, a leader in ... and colors represent a sophisticated response to contemporary ... team of Koroseal experts, Modernfold reviewed hundreds of ...

(Date:5/23/2013)... that can cause rapidly progressing, life threatening meningitis and ... we have not known how it attaches to the ... it attaches to the airway to colonise", People can ... symptoms, while some people progress to invasive disease. ... of how the bacterium colonises the airway. Now that ...

(Date:5/23/2013)... to a new market report "Service Delivery Platform (SDP) ... Telecom Application Server; Service Creation Environment; Orchestration Environment] - ... MarketsandMarkets, the SDP Market is expected to reach $6.94 ... 2013 to 2018. , Browse:, , ... , 189 Pages and an in-depth Table ...

(Date:5/23/2013)... May 23, 2013 Verndale, an ... the launch of Current Digital, a business dedicated ... and digital marketing needs. Companies now view content ... business necessity. This can often leave agencies placed ... on preselected software platforms that they may not ...

Breaking Medicine News(10 mins):Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2 Health News:New discovery in fight against deadly meningococcal disease 2 Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2 Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3 Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2 Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3

[0] New State Teen Birth Data Released; Declines in 48 States from 2007 through 2011 - A Statement from the National Campaign to Prevent Teen and Unplanned Pregnancy [0] Modernfold Debuts New Colors and Patterns for Space Division Products [0] New discovery in fight against deadly meningococcal disease [0] Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets [0] Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies

... HealthDay Reporter , TUESDAY, April 10 (HealthDay News) -- U.S. ... -- a man-made version of the hormone progesterone -- may ... will require new labels. The U.S. Food and Drug ... pills -- which include products such as Bayer,s Yaz or ...

... HealthDay Reporter , TUESDAY, April 10 (HealthDay News) ... heart test -- an electrocardiogram, or EKG -- translate into ... heart attacks, hospitalizations for chest pain or the need for ... For people with major abnormalities in their EKG, the ...

... TUESDAY, April 10 (HealthDay News) -- American youngsters have a long ... childhood obesity rate, a new study shows. The U.S. Department ... the childhood obesity rate to 14.6 percent by 2020, and to ... an average of 64 calories a day. Without this reduction ...

... in low- and middle-income countries, and there is an ... help tackle the disease, states an analysis in CMAJ ... more people than HIV/AIDS, tuberculosis and malaria combined. The ... rise through 2030 of 82% in low- and lower-income ...

... be good for your health, particularly when parental support ... Boston University School of Public Health (BUSPH) researcher Emily ... adults in a representative Massachusetts sample reported receiving positive ... Their incidence of mental health and substance abuse problems ...

... American Society of Pediatric Otolaryngology (ASPO) will hold its ... 2012 Combined Otolaryngology Spring Meetings (COSM) - a joint ... During the ASPO meeting, hundreds of pieces of ... panelists will be presented focusing on children,s ear, nose, ...

Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA EKG Heart Test May Predict Risk in Older Adults Young Americans Need to Cut Calorie Intake: Study Canada should play a role in addressing the global cancer epidemic Supporting LGB children may influence their long-term health, BU study finds Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting

... The TOPCON 3D+ ALE-3700/3700PC/3700CF patternless processing ... to frame, quickly, accurately and with the ... incorporates the 3D+ FR-20 Frame Reader, advanced ... system is available with a polycarbonate feature ...

... Cutting-edge technology enables a fast, precise ... every time. Introducing the TOPCON ALE-X1. The ... a host of improved features and functions. ... both flat and beveled edges, precise three-dimensional ...

...

... TOPscan Dispensers used to only have two choices ... the completed job at a wholesale lab, which ... alternative was to finish the order in house, ... offices required another edger, lens inventory, more space ...

Medicine Products:

TOPCON ALE-3700 patternless lens edger TOPCON ALE-X1 Paternless Lens Edger Topcon PS-9 Manual Blocker Topcon Remote Tracing Software